Search the Newsreel

GeoVax Labs Inc (GOVX) Earnings Forecast: Future EPS & Revenue Growth Estimates

GeoVax Labs Inc (GOVX) has an earnings forecast score of 8.00, ranking 171 out of 387 in its industry. Analysts have set an average price target of $8.50, with a significant upside potential of over 10000% based on two analysts' Buy recommendations. The company's …

A Quick Look at Today's Ratings for BioAge Labs(BIOA.US), With a Forecast Between $21 to $73

This article provides a brief overview of recent analyst ratings for BioAge Labs (BIOA.US), highlighting a wide forecast range for its stock price between $21 and $73. It indicates that these ratings come from investment analysts who are evaluating the company's future performance.

Earnings call transcript: Blend Labs beats Q2 revenue forecast, shares fall after hours

Should Investors Hold on to Astera Labs Stock Post Q2 Earnings?

Astera Labs (ALAB) shares have fallen 12% since its Q2 2026 earnings report, primarily due to higher operating expenses despite strong demand for its AI connectivity products. The company's stock has outperformed the broader tech sector year-to-date, driven by its Scorpio, Aries, and Taurus …

Earnings call transcript: Establishment Labs tops revenue in Q2 2026, shares slip

Establishment Labs (NASDAQ:ESTA) Releases Earnings Results

BioAge Labs, Inc. Stock 12‑Month Price Target Cut to $35.62, Implies 224% Upside

BioAge Labs, Inc. (BIOA) has seen its average 12-month price target cut to $35.62 from $39.88, according to 8 analysts, yet this still implies a significant 224% potential upside based on its closing price. Despite the target reduction, the consensus rating from 9 analysts …

Astera Labs Beat And Guided Higher, Then Fell Because The Rally Came First

Image from Pixabay A record quarter and a guide above expectations met a stock that had already climbed for four straight sessions, and the mix underneath that growth is what actually changed. Astera Labs (ALAB), which sells connectivity silicon for rack-scale AI systems, reported …

VivoSim Labs regains Nasdaq compliance after cash infusion

VivoSim Labs (NASDAQ:VIVS) has regained compliance with Nasdaq listing rules after receiving a $5.0 million milestone payment from Eli Lilly, a $1.0 million release from escrow, and completing a $4.0 million financing round. These financial infusions, which occurred in July 2026, increased the company's …

Shattuck Labs (STTK) Projected to Release Earnings on Thursday

Shattuck Labs (NASDAQ:STTK) is projected to release its Q2 2026 earnings before market open on Thursday, August 13th, with analysts anticipating a loss of $0.1241 per share. The company's stock has seen substantial growth from its one-year low, and institutional investors hold a significant …

Shattuck Labs, Inc. (NASDAQ:STTK) Given Average Rating of "Moderate Buy" by Brokerages

Shattuck Labs, Inc. (NASDAQ:STTK) has received an average "Moderate Buy" rating from brokerages, with an average 12-month price target of $12.63, significantly above its current share price of $7.37. Recent analyst updates from Needham, Wedbush, and Leerink Partners have been positive, raising price targets …

Needham raises Establishment Labs stock price target on strong results

Thinkific Tops Q2 Revenue Guidance as Plus Segment Grows, Targets Higher Profitability

Blend Labs (NYSE: BLND) cuts losses, buys back $36.8M in stock

Blend Labs Inc. (NYSE: BLND) reported narrower losses for the three and six months ended June 30, 2026, with Q2 revenue of $33.8 million and six-month revenue of $64.7 million. The company's net loss significantly improved to $9.5 million for the six months, alongside …

Canaccord raises Establishment Labs stock price target on strong US growth

PancakeSwap Expands Tokenized Equity Offerings with 10 New 'bStocks' on BNB Chain

PancakeSwap Expands Tokenized Equity Offerings with 10 New 'bStocks' on BNB Chain Decentralized crypto exchange PancakeSwap (CRYPTO: $CAKE) expanded its tokenized equities offering on Thursday, listing 10 additional "bStocks" on BNB Chain to give users 24-hour access to shares of high profile companies ranging …

Is Establishment Labs Holdings (ESTA) Undervalued After Its Earnings Beat And Raised Guidance?

Astera Labs vs. AppLovin: Which Technology Stock Is a Better Buy in 2026?

The surge in artificial intelligence has created two distinct winners in the hardware and software sectors. Choosing between Astera Labs (NASDAQ:ALAB) and AppLovin (NASDAQ:APP) requires weighing specialized connectivity against advertising scale. Astera Labs provides the physical connectivity that allows AI servers to communicate at …

Astera Labs, Inc. (ALAB): New Buy Recommendation for This Technology Giant

Jefferies analyst Blayne Curtis maintained a Buy rating on Astera Labs, Inc. (ALAB) with a price target of $450.00, following strong Q1 earnings where the company reported $308.36 million in revenue and $80.31 million in net profit. While Roth MKM also issued a Buy …

Astera Labs (ALAB) Stock May Sit Above Fair Value On Cash Flow And Earnings

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Astera Labs stock has delivered a strong 86.3% return over the past year, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and market …

Establishment Labs earnings up next: Can U.S. growth sustain?

Establishment Labs is set to report Q2 earnings, with analysts expecting a loss of 34 cents per share on revenue of $65.8 million, a 28% jump year-over-year. Investors are keenly watching the medical device maker's ability to sustain growth in the U.S. market, particularly …

Establishment Labs (ESTA) lifts 2026 outlook after 31.7% Q2 revenue growth

Establishment Labs Holdings Inc. reported strong Q2 2026 revenue of $67.5 million, marking a 31.7% year-over-year increase, driven by significant growth in Motiva USA and minimally invasive platforms. The company raised its full-year 2026 revenue guidance to $269–$271 million, reflecting increased confidence in continued …

BioAge Labs, Inc. Q2 2026: Revenue $2.45M, EPS $(0.58) — 10-Q Summary

BioAge Labs, Inc. reported its second-quarter 2026 results, showing flat revenue year-over-year at $2.45 million and a wider net loss, with a diluted loss per share of $(0.58). Despite the financial performance, the company highlighted positive clinical progress for BGE-102, advancement in its QUELL-CV …

Blend Labs, Inc. SEC Filing (Aug 5, 2026)

Blend Labs, Inc. (BLND) filed a Form 144 with the SEC on August 5, 2026, indicating a proposed sale of securities. The filing details the sale of 15,041 shares of common stock through Charles Schwab & Co., Inc. with an aggregate market value of …

Establishment Labs Q2 2026 earnings: U.S. growth lifts gross margin

Establishment Labs (NASDAQ: ESTA) reported strong Q2 2026 results with revenue up 31.7% year-over-year, driven largely by significant growth in its U.S. business and minimally invasive product platform. This favorable mix improved gross margin to 70.6% and adjusted EBITDA to a positive $3.7 million, …

20/20 Biolabs to host investor webinar; reports best quarterly cancer-test revenue to date

20/20 Biolabs announced its preliminary Q2 2026 cancer-testing revenue as its best quarter to date and will host an investor webinar on August 5, 2026. The company secured 29 new commercial orders, including large firefighter programs, and is piloting a new product with Giant …

BioAge Labs, Inc. (BIOA) Stock Price, News, Quote & History

This Yahoo Finance page provides a comprehensive overview of BioAge Labs, Inc. (BIOA) stock, including its current price, historical data, company profile, and financial performance. It highlights key financial metrics, analyst ratings, and recent stock performance compared to the S&P 500, detailing the company's …

VivoSim regains Nasdaq compliance after $10.1 million cash update

VivoSim Labs (VIVS) has announced that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which mandates a minimum stockholders’ equity of $2.5 million. This compliance was achieved through several events in July 2026, including a $5.0 million milestone payment from Eli Lilly, a …

VivoSim Provides Financial and Listing Compliance Update

VivoSim Labs, Inc. announced it has regained compliance with Nasdaq Listing Rule 5550(b)(1) requiring a minimum stockholders’ equity of $2.5 million. This compliance was achieved through significant financial events in July 2026, including a $5.0 million milestone payment from Eli Lilly and Company, $1.0 …

VivoSim reports 13.4M shares outstanding after July warrant exercises

VivoSim (VIVS) announced it has regained compliance with Nasdaq Listing Rule 5550(b)(1) after receiving a $5.0 million milestone payment and $1.0 million escrow release from Eli Lilly, along with $3.6 million net proceeds from a financing. The company reported $10.1 million cash on hand …

Astera Labs, Inc. Stock 12‑Month Price Target Raised to $391.01, Implies 8% Upside

Astera Labs, Inc. (ALAB) has seen its average 12-month price target raised to $391.01 by 21 analysts, suggesting an 8% upside from its Aug. 4 closing price. The consensus rating for the stock remains a "Buy" from 24 analysts, with a breakdown of 15 …

Establishment Labs GAAP EPS of -$0.39 misses by $0.05, revenue of $67.5M beats by $1.72M

* Establishment Labs press release [https://seekingalpha.com/pr/20609818-establishment-labs-reports-second-quarter-2026-financial-results] (ESTA [https://seekingalpha.com/symbol/ESTA]): Q2 GAAP EPS of -$0.39 misses by $0.05. * Revenue of $67.5M (+31.6% Y/Y) beats by $1.72M. * $24.7 million of sales in the United States, up 26% from Q1 2026 * Guidance raised to $269 …

Up 58% in 12 Months, This Is Where Rocket Lab Will End The Year

Quick Read RKLB earns a BUY with an $82 year-end target, backed by 63% revenue growth and a record $2.2 billion backlog. ASTS posts just $15M in quarterly revenue on a $17.5B market cap, while Planet Labs carries roughly one-fifth of RKLB's $41B valuation. …

BioAge Labs Reports Q2 2026 Results, Doses First Patient in QUELL-CV and Advances BGE-102 Clinical Development

BioAge Labs announced its Q2 2026 results, reporting a net loss of $26.1 million, but also significant progress in its clinical trials. The company dosed the first patient in its QUELL-CV Phase 2 trial for BGE-102, targeting inflammation and cardiometabolic biomarkers, with topline data …

Astera Labs and Amphenol: Quiet AI Capex Tax Collectors to Know Before Others Catch On

The article analyzes Astera Labs (ALAB) and Amphenol (APH) as beneficiaries of AI infrastructure spending. Astera Labs, focused on AI fabric silicon, saw revenue double year over year, while Amphenol, with diversified offerings, grew 55% to $8.76 billion. The author suggests Astera offers higher …

Aurora Labs (ASX:A3D) Advances as Defence Additive Manufacturing Work Develops